New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 30, 2013
16:06 EDTQDELQuidel receives FDA clearance for sale of AmpliVue Group B Strep Assay
Quidel announced that it has received 510(k) clearance from the FDA for the sale of its AmpliVue Group B Strep Assay. AmpliVue is Quidel's non-instrumented molecular diagnostic test that employs a novel amplification technology with an easy-to-use, hand-held device. The AmpliVue Group B Strep Assay combines isothermal Helicase Dependent Amplification, or HDA, with Quidel's well-established expertise in lateral flow technology to detect Group B Streptococcus, or GBS, from enriched broth cultures of specimens from antepartum women.
News For QDEL From The Last 14 Days
Check below for free stories on QDEL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
07:51 EDTQDELQuidel price target lowered to $28 from $35 at Canaccord
Canaccord lowered its price target on Quidel following its Q1 earnings miss. The firm noted the miss was due to a drop off in flu patients but is maintaining its Buy rating on expectations of a large new product cycle led by Sofia.
April 23, 2014
16:16 EDTQDELQuidel reports Q1 EPS ex-items 8c, consensus 30c
Subscribe for More Information
April 22, 2014
14:31 EDTQDELQuidel receives FDA clearance to market Lyra Direct Strep Assay
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use